C Caggiano, M Morselli, X Qian, B Celona, M Thompson, S Wani, A Tosevska, K Taraszka, G Heuer, S Ngo, F Steyn, P Nestor, L Wallace, P McCombe, S Heggie, K Thorpe, C McElligott, G English, A Henders, R Henderson, C Lomen-Hoerth, N Wray, A McRae, M Pellegrini, F Garton, N Zaitlen
Cell-free DNA (cfDNA) is increasingly recognized as a promising biomarker candidate for disease monitoring. However, its utility in neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS), remains underexplored. Existing biomarker discovery approaches are tailored to a specific disease context or are too expensive to be clinically practical. Here, we address these challenges through a new approach combining advances in molecular and computational technologies. First, we develop statistical tools to select tissue-informative DNA methylation sites relevant to a disease process of interest...
April 10, 2024: medRxiv